Vast Therapeutics Lands $15M Series A Funding, CF Foundation Funding

computer-3343887_1280
January 16, 2019
By Shellie

Vast Therapeutics is celebrating the new year with Series A funding in excess of $15 million from Shionogi & Co., Ltd. (TYO: 4507) of Japan and a $300,000 award from the Cystic Fibrosis Foundation.

The Durham company, which changed its name in mid-2018 from Novoclem Therapeutics, will use the CF award to support toxicology studies this spring.

The Series A funding will support bringing the molecule BIOC51 to first-in-human clinical trials later in the year, according to John Oakley, Vast’s chief financial officer. The company anticipates submitting an lnvestigational New Drug application in 2019.

Story by WRAL TechWire

Read full article